Till innehåll

Share issue
2022

Oncopeptides has carried out a directed share issue of approximately SEK 435.6 million (approximately USD 41.1 million)

July 14, 2022 – Regulatory press release

The Board of Directors of Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) (Nasdaq Stockholm: ONCO) has resolved to issue 15,061,443 new shares (the “New Shares”) in a directed share issue to international and Swedish institutional investors based on the authorization granted by the Annual General Meeting on 28 June 2022 (the “Directed Share Issue”). The price for the New Shares is SEK 28.92 per new share, corresponding to the closing price on the day of this announcement of the Oncopeptides share, as traded on Nasdaq Stockholm. A number of international and Swedish investors participated in the Directed Share Issue, including new investors such as Redmile Group, HealthCap VIII and Adrigo Asset Management, as well as the existing shareholders HealthCap VI, Industrifonden and Swedbank Robur Fonder, with demand for the New Shares exceeding the size of the Directed Share Issue. Through the Directed Share Issue, Oncopeptides will receive proceeds amounting to approximately SEK 435.6 million (approximately USD 41.1 million) before transaction costs.

On this page

Select language or region
Region

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Disclaimer

Access to the information and documents on this part of the website is restricted for regulatory reasons. You are requested to review the following information and make the following confirmation each time you seek to access this restricted information. Your confirmation must be true and accurate.

Please scroll through all the information above to continue.

Not sure if you can access the content? Click here to read the full terms.